Based upon preclinical data, it was believed that continuous kinase inhibition is a prerequisite for successful TKI treatment: It has been shown in a chronic myeloid leukemia (CML) mouse model that prolonged inhibition of BCR-ABL is necessary to eradicate the disease. 7 In line with this, clinical trials identified a close relationship between imatinib serum trough-levels and clinical effectiveness. 8, 9 In 2008, Shah et al. 10 introduced the concept that transient potent BCR-ABL inhibition irreversibly commits CML cells to apoptosis. Consecutively, other groups published similar data on dasatinib and nilotinib. 11, 12 Very recently, we have performed a comprehensive investigation on the molecular mechanisms involved in apoptosis induced upon transient kinase inhibition. 13 Interestingly, cellular TKI accumulation and retention was identified as the underlying molecular mechanism of induction of apoptosis upon high-dose TKI (HD-TKI) pulse-exposure using either imatinib or dasatinib. 13 Based upon these findings, we here investigated the behavior of nilotinib when applied as high-dose pulse using an established in vitro model of BCR-ABL transformation. For this purpose, Ba/ F3-BCR-ABL cells were treated for 2 h with 1 mM nilotinib, followed by thorough repetitive drug wash out with phosphate-buffered saline, each consisting of two rounds of media exchange ('1x'). This procedure was repeated 2 and 4 h after reseeding of cells in TKI free cell culture media ('2x', '3x'). Before washing, cell culture supernatants were transferred to previously untreated cells ('S1', 'S2', 'S3') ( Figure 1a ). Apoptosis as assessed by propidium iodide staining after 24 h showed high levels of apoptotic cell death following nilotinib pulse-treatment ( Figure 1a , '1x'), which is in line with published data. [10] [11] [12] [13] Upon repeated washing, we observed a partial rescue from apoptosis. However, in contrast to our previous findings employing imatinib and dasatinib, this rescue was incomplete ( Figure 1a '2x', '3x'). Transferred supernatants showed TKI activity by inducing cell death in previously untreated cells, indicating the presence of biologically relevant nilotinib concentrations ('S2', 'S3'). Employing two other apoptosis assays (staining for AnnexinV and intracellular cleaved caspase3) we were able to confirm these data (Figures 1b and c) . As a control, Ba/F3 parental cells did not undergo apoptosis after nilotinib pulse-treatment, indicating the absence of cytotoxic off-target effects at the TKI concentrations used (data not shown). We also tested the effects of nilotinib pulse-exposure on the human CML cell line K562 and similarly, we observed a gradual decrease in the percentage of apoptotic cells upon repetitive washing (data not shown). Then we investigated the effects of ABC-transporter expression on apoptosis upon HD-TKI pulse-exposure. Therefore, we used K562 cells overexpressing either ABCB1 or ABCG2. Nilotinib pulsetreatment of cells overexpressing either transporter protein resulted in decreased levels of apoptosis as compared with nilotinib pulse-treated K562 wild-type controls. The difference reached statistical difference for K562 cells overexpressing ABCG2 (Figure 1d ). This observation is in line with publications showing that ABC-transporter expression reduces responsiveness of BCR-ABL-positive cells to TKI treatment. 14, 15 Based on these findings, activity of important signaling pathways was assessed by western blot: While P-CRKL showed marked rephosphorylation after the first drug wash out, P-STAT5 and BCR-ABL (Y412) remained dephosphorylated ('1x') and showed only incomplete recovery of phosphorylation ('2x', '3x') as compared with the untreated control ('M') even after the third round of washing ( Figure 2a ). In contrast, phosphorylation of BCR-ABL (Y177) seemed to be largely unaffected even upon continuous nilotinib exposure for 2 and 10 h. Western blot analysis of nilotinib pulse-treated K562 cells revealed similar results (Figure 2b ). Results of propidium iodide staining and western blotting suggested that nilotinib might be enriched intracellularly upon pulse-exposure. Furthermore, slow release into the cell culture media has been described for other TKI upon HD-TKI pulse. 13 To quantify a potential nilotinib release into the media after drug wash out, a novel liquid chromatography (LC)/mass spectrometry (MS)/MS assay was used. 16 BCR-ABL þ murine and human cell lines, as well as primary human cells from CML patients and from healthy donors were treated as described above. LC/MS/MSmeasurements of cell culture supernatants after drug wash out revealed a time-dependent increase of nilotinib, reaching concentrations far above the in vitro IC 50 (Figure 2c) . 17 Using the same assay, we measured nilotinib in lysates of BCR-ABL þ cells after nilotinib incubation. Based on the cellular volume that was derived by calculation from cell diameter measurements (total cellular volume for 0.2 Â 10 6 cells was calculated to be 0.19 ml for Ba/F3-BCR-ABL cells and 0.5 ml for K562 cells), we then calculated the intracellular TKI concentration (for details, please see Lipka et al.
13
). Thus, we determined the intracellular nilotinib peak concentration upon 2 h exposure to 1 mM nilotinib to be about 960 mM for Ba/F3-BCR-ABL cells and 261 mM for K562 cells. This demonstrates that nilotinib dramatically accumulates intracellularly. Taken together, our data indicate intracellular TKI retention upon nilotinib pulse-exposure, which translates into prolonged inhibition of BCR-ABL kinase, resulting in induction of apoptosis. These results are in line with recently reported data on imatinib and dasatinib. 13 Previous publications already had suggested that transient but potent kinase inhibition can efficiently induce apoptosis. [10] [11] [12] However, our data presented here and in Lipka et al. 13 add a novel view to this concept: we provide evidence that transient kinase inhibition is not sufficient to induce apoptosis. Instead, nilotinib (but also imatinib and dasatinib 13 ) dramatically accumulates intracellularly upon HD-TKI pulse-exposure. This then results in prolonged intracellular TKI exposure even after drug removal in the surrounding media.
In the case of nilotinib, we here observed relatively high levels of apoptosis even after three rounds of drug wash out Accepted article preview online 12 December 2012; advance online publication, 11 January 2013 Leukemia (2013) Figures 1a-c, '3x' ), which might be due to even more prolonged intracellular TKI retention of nilotinib as compared with imatinib and dasatinib. Data presented by Manley et al. 18, 19 showing increased residence time of nilotinib further support this hypothesis. Nevertheless, further investigations involving a direct comparison of different TKI are needed to define differential cellular retention profiles. As published recently for imatinib and dasatinib, 13 we would like to point out that phosphorylation dynamics of signaling pathways upon repetitive drug wash out differ for BCR-ABL(Y412) in comparison with BCR-ABL(Y177), and for STAT5 in comparison with CRKL. In our view, this explains why in previous work relevant residual TKI levels were considered to be ruled out. [10] [11] [12] Taken together, our data presented here underline our previous findings that HD-TKI pulse-exposure confers apoptotic cell death by prolonged intracellular TKI activity. Our data indicate that monitoring not only plasma but also intracellular drug levels of TKI may have the potential to optimize dosing schedules. Furthermore, our data indicate that nilotinib might exhibit more prolonged intracellular retention as compared with imatinib and dasatinib. This interesting point has to be clarified in further studies directly comparing different TKI for their capacity of intracellular accumulation and retention. These data might then provide a rationale for clinical trials testing once daily or discontinuous TKI dosing for chronic myeloid leukemia. 4 cells/ml) were exposed for 2 h to 1 mM nilotinib and subsequently underwent repetitive wash out procedures as described earlier. 13 Cells exposed to 0.1% dimethyl sulfoxide served as controls ('M'). '1x' , '2x' , '3x': Cells were treated with HD-TKI for 2 h and drug wash out was performed in 2 h intervals. Furthermore, cell culture supernatants were transferred to previously untreated cells before each washing ('S1' , 'S2' , 'S3'). Percentage of cells in subG1 phase at 24 h was determined by propidium iodide staining. Experiments were performed in triplicate and are shown þ s.e.m. (a) As additional apoptosis assays we determined levels of annexinV-staining (b) and caspase3-cleavage using flow-cytometry (c). One representative experiment is shown in (b) and (c). Impact of ABCtransporter overexpression on HD-TKI-induced cell death: (d) K562, K562-ABCB1 and K562-ABCG2 cells were treated with 1 mM nilotinib for 2 h followed by single drug wash out procedure. Percentage of cells in subG1 phase at 24 h was determined by propidium iodide staining. Experiments were performed in triplicate and are shown þ s.e.m. The asterisk (*) indicates Po0.05 in a two-tailed t-test.
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Initially disadvantaged, TEL-AML1 cells expand and initiate leukemia in response to irradiation and cooperating mutations Although TEL-AML1 is present in one-fourth of childhood precursor B-cell acute lymphoblastic leukemia (pre-B ALL), the expression of the ETV6-RUNX1 gene encoding this fusion protein has been a poor initiator of leukemia in multiple mouse models. [1] [2] [3] [4] [5] [6] [7] [8] To gain insight into why this common lesion does not readily initiate disease, we took advantage of a novel mouse model, in which TEL-AML1 expression was linked to a fluorescence marker and could be induced in a subset of hematopoietic cells during embryonic development. The laboratory of Corrinne Lobe had generated a reporter mouse in which enhanced green fluorescent protein (EGFP) was expressed following Cre-mediated excision (designated herein as ZEG mice), and subsequently generated an analogous mouse, in which a human TEL-AML1 encoding complementary DNA and an internal ribosomal entry site were placed upstream of EGFP (designated herein as TA1 mice). We crossed the inducible ZEG and TA1 mice with mice expressing Cre under the control of the Tie2(Tek) promoter, which is expressed in endothelial cells as well as during early hematopoietic development. These crosses resulted in mice carrying either the Tie2-Cre and inducible ZEG transgenes (Cre/ZEG mice) or the Tie2-Cre and inducible TA1 transgenes (Cre/TA1 mice). Mice carrying the inducible TA1 transgene but lacking Cre were also generated (Cre-/TA1 þ control mice).
The Tie2-Cre cassette resulted in EGFP expression in most, but not all, mature hematopoietic cells of Cre/ZEG mice (Figures 1a  and b) . The fact that Tie2-Cre resulted in variegated EGFP expression enabled us to determine whether TEL-AML1 expression had a selective advantage or disadvantage on hematopoietic development. If TEL-AML1 provided a selective advantage in Cre/ TA1 mice, we expected the percentage of EGFP expressing cells to be increased relative to that observed in the Cre/ZEG mice. However, if TEL-AML1 provided a selective disadvantage, EGFP expressing cells would be decreased relative to the Cre/ZEG control. We initially surveyed 5-week-old mice for induction of EGFP in various hematopoietic tissues (Figure 1b) . We did not observe any cell type in which TEL-AML1 provided a selective advantage. There was a clear selective disadvantage of TEL-AML1 in B-cells and in T-cells. TEL-AML1 had a modest negative impact on the development of bone marrow myeloid cells and, interestingly, was somewhat tolerated by peritoneal B-cells.
We also took advantage of mice that were part of our survival study (see below) to assess how TEL-AML1 impacted hematopoiesis in aging mice. TEL-AML1 did not impact the fitness of hematopoietic stem and most progenitor cells, but was selected against in megakaryocyte-erythroid progenitors (MEP, Figure 1c) . Results in these aged mice confirmed a selective disadvantage in maturing lymphocytes, as well as a sizeable disadvantage during granulopoiesis in older mice (Figure 1d ). The substantially impaired contribution to granulopoiesis in older mice might reflect an interaction of TEL-AML1 with the shifting hematopoietic stem/early progenitor numbers and lineage output that occur in aged mice. 9, 10 However, as shown in Supplementary Figure S1 , TEL-AML1 expression had no impact on survival.
Low-dose radiation can cause lymphoid tumors in mice (Gross et al. 11 and references therein). We irradiated Cre/ZEG and Cre/TA1 mice at 5 and 6 weeks of age with 1.7 Gy. We observed the impact of this irradiation on the percentage of cells in the peripheral blood that expressed EGFP and on survival. Cre/ZEG mice had a high percentage of EGFP expressing cells in their peripheral blood whether or not they were irradiated (Figure 1e ). This high percentage of EGFP was seen in cells with low side scatter (primarily lymphocytes) and cells with higher side scatter (primarily granulocytes). In contrast, Cre/TA1 mice had low levels of EGFP in the blood before irradiation (greater expression of EGFP was observed in granulocytes than in lymphocytes), and the percentage of GFP increased greatly in the blood (in both the low and higher side scatter blood cells) when assessed 5-14 months after irradiation. Irradiation curtailed survival and induced tumors in both the Cre/ZEG and Cre/TA1
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